At Bozzuto Group, we’ve built our practice around one core belief: emerging industries deserve expert insurance partners who actually understand their world. We’ve been at the forefront of insuring cannabis, hemp, CBD, nutraceuticals, and wellness brands for years — long before most carriers were willing to step into these spaces. So when a major regulatory shift like this one happens, we pay close attention. And so should you.
On April 15, 2026, the U.S. Food and Drug Administration announced one of the most consequential regulatory changes for the peptide and compounding industry in years: 12 peptide-based bulk drug substances will be removed from FDA Category 2 — the classification reserved for compounds deemed to raise significant safety concerns. This announcement, driven by HHS Secretary Robert F. Kennedy Jr., signals a fundamental reset in how regulators view these widely researched compounds.
For businesses operating in the peptide, compounding, wellness, and regenerative medicine space, this is a major development. For insurance companies and brokers like us who protect those businesses, it’s equally significant.
What Just Changed — And Why It Matters
To appreciate the significance of this update, a little background is helpful.
In September 2023, the FDA placed a wide range of popular peptides into Category 2 of its Section 503A bulk drug substances list. Category 2 was specifically reserved for substances considered to raise significant safety risks, and placement there effectively barred compounding pharmacies from using these compounds when preparing medications for individual patients. For practitioners, compounders, and wellness companies relying on these therapies, it was a sweeping and disruptive restriction.
The 12 peptides now being removed from Category 2 include some of the most widely researched compounds in regenerative and functional medicine:
- BPC-157 — studied for tissue repair and gut healing
- TB-500 — a thymosin beta-4 fragment supporting cell migration and recovery
- Semax — a neuropeptide researched for cognitive support
- Epitalon — explored for anti-aging and telomere effects
- MOTS-C — a mitochondrial peptide studied for metabolic function
- KPV — researched for anti-inflammatory effects
- PEG-MGF — a mechano growth factor studied for muscle repair
- Melanotan II — researched for pigmentation and other effects
- LL-37 (Cathelicidin) — an antimicrobial peptide with immune applications
- DiHexa — studied for neuroprotective properties
- DSIP (Emideltide) — researched for sleep regulation
- GHK-Cu (injectable routes) — a copper peptide with regenerative research behind it
Effective April 22, 2026, these compounds exit the significant-safety-concerns list. Each will be referred to the Pharmacy Compounding Advisory Committee (PCAC) for independent scientific evaluation, with public meetings beginning in July 2026. This process gives these compounds a fair, evidence-based hearing — rather than a blanket restriction.
A Positive Shift for the Insurance Industry
Here’s the part that directly affects us as your insurance partner: regulatory clarity is one of the most powerful risk-reduction tools in our industry.
When compounds are stuck in a gray zone — restricted by regulation yet still sought by patients and practitioners — the result is a fragmented market operating partly in the shadows. Unregulated sourcing, inconsistent product quality, and unclear legal standing make it difficult for insurers to accurately underwrite risk. Carriers pull back. Premiums spike. And businesses that are operating responsibly struggle to get the coverage they need at rates that make sense.
The removal of these peptides from Category 2 begins to change that equation in several meaningful ways:
Greater regulatory clarity enables better risk assessment. Insurance underwriting is fundamentally about understanding risk. When businesses operate in a well-defined regulatory framework — even one that is still evolving — carriers can evaluate exposure with far greater confidence. The PCAC review process, with its public meetings, evidence standards, and transparent timelines, provides exactly that kind of structured clarity.
Reduced black market activity lowers product liability exposure. One of the most significant risks for peptide and wellness companies is product liability — and that risk is dramatically elevated when consumers turn to unregulated sources. The 2023 Category 2 restrictions didn’t eliminate demand for these peptides; they pushed it underground. Bringing these compounds back into a regulated compounding pathway means more patients getting products from licensed, quality-controlled pharmacies. That directly reduces the likelihood of adverse events tied to contamination, mislabeling, or improper dosing — and the liability claims that follow.
A clearer legal pathway supports business continuity coverage. Business interruption and professional liability insurance both depend on a company’s ability to demonstrate a lawful, stable operating model. For practitioners and compounders who had to abruptly stop offering these therapies in 2023, that stability was shattered. The pathway being opened now allows businesses to rebuild and expand with greater confidence — and with insurance programs that can actually reflect their real operations.
It opens the door for more carriers to enter the space. Specialty markets attract specialty carriers — but only when there’s enough regulatory infrastructure to make underwriting viable. As the PCAC process unfolds and these peptides potentially move toward formal approval or recognized compounding status, we expect broader carrier interest in this segment. That means more competition, more options, and ultimately better coverage terms for the businesses we insure.
What This Means for Businesses We Protect
If you’re operating in the peptide, compounding, regenerative medicine, or functional wellness space, here is what you should be thinking about right now:
Review your current coverage. Many businesses in this space have been operating under coverage that was structured around the constraints of the 2023 restrictions. As the regulatory landscape shifts, your policy language and coverage limits may need to be revisited to reflect your actual and evolving operations.
Document your compliance posture. Insurers want to see that you are tracking regulatory changes and adjusting your practices accordingly. The PCAC process has a clear timeline — July 2026 meetings, with GHK-Cu and others reviewed through early 2027. Staying current with those proceedings and demonstrating compliance readiness will strengthen your insurability.
Understand product liability exposure in the transition period. The removal from Category 2 is effective, but these peptides are not yet fully approved for compounding — they are entering a review phase. During this transition, clarity around sourcing, labeling, and quality control is especially important from a liability standpoint.
Talk to a broker who knows this space. This is not the time for a generalist. The peptide and compounding industry has unique risk profiles that require a broker with deep expertise in natural products, emerging wellness markets, and specialty liability. At Bozzuto Group, this is exactly what we do.
Our Perspective: This Is the Direction the Industry Needed
We have long believed that innovation in health and wellness deserves a regulatory environment that keeps pace with the science — and insurance solutions that keep pace with regulation. For too long, promising compounds with substantial research behind them were caught in a framework that wasn’t built to evaluate them fairly.
The 2026 FDA update doesn’t resolve everything overnight. The PCAC process is just beginning, and the ultimate status of each of these peptides will depend on the scientific review that follows. But the direction is unmistakably positive: toward evidence-based evaluation, toward regulated access, and away from the enforcement-without-clarity approach that characterized the last few years.
For the businesses we insure — peptide manufacturers, compounding pharmacies, functional medicine clinics, nutraceutical brands, and wellness companies — this is an opportunity to operate with greater confidence and greater legitimacy. And for Bozzuto Group, it’s an opportunity to continue doing what we do best: building insurance programs that protect innovators in the industries shaping the future of health.
Bozzuto Group specializes in tailored insurance solutions for emerging and established industries, including cannabis, hemp, CBD, nutraceuticals, natural products, and wellness brands. To discuss coverage for your business in light of this regulatory update, reach out to our team at bozzutogroup.com.